FLT3-IN-5e|FLT-3 inhibitor 5e

Cas No.:	2093038-25-4
Chemical Name:	N4-Isopropyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-diamine
Synonyms:	FLT-3 inhibitor 5e
SMILES:	C(NC1=CC=CC(C2=CC=CN=C2)=C1)1=NC=CC(NC(C)C)=N1
Formula:	C₁₈H₁₉N₅
M.Wt:	305.385
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

FLT3-IN-5e is a nove potent, selective FLT3 inhibitor with Kd of 3.6 nM, IC50 of <6 nM; has high potentcy against mutant FLT3 D835H, D835V, D835Y, ITD-D835V, ITD-F691L, K663Q, N841I, and R834Q (Kd=0.36-82 nM); shows weak (8-fold selectivity) activity for PDGFRB (28 nM) and the JAK1 JH2 domain (28 nM); possesses growth inhibitory potencies against MOLM13 FLT3-ITD and MOLM13 FLT3-ITD/D835Y cells.

Cat. No.	Product name	Field of application
DC47657	LT-850-166	LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations.
DC46932	Luxeptinib	Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.
DC44089	FLT3-IN-4	FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia.
DC28136	Tandutinib hydrochloride	Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier.
DC11780	FLT3-IN-5e	FLT3-IN-5e is a nove potent, selective FLT3 inhibitor with Kd of 3.6 nM, IC50 of <6 nM.
DC10922	AAE871	AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity..